Impact of pazopanib on docetaxel exposure: results of a phase I combination study with two different docetaxel schedules.

Purpose There are several reasons why combining an inhibitor of the vascular endothelial and the platelet-derived growth factor receptor with a taxane might induce synergistic antitumor activity. This phase I study aimed to determine the maximal tolerated dose (MTD) of the combination of pazopanib with two different schedules of docetaxel.